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Syntaxin 1 is an essential component of the neuro-
transmitter release machinery, and regulation of syn-
taxin 1 expression levels is thought to contribute to the
mechanism underlying learning and memory. However,
the molecular events that control the degradation of
syntaxin 1 remain undefined. Here we report the iden-
tification and characterization of a novel RING finger
protein, Staring, that interacts with syntaxin 1. Staring
is expressed throughout the brain, where it exists in
both cytosolic and membrane-associated pools. Staring
binds and recruits the brain-enriched E2 ubiquitin-con-
jugating enzyme UbcH8 to syntaxin 1 and facilitates the
ubiquitination and proteasome-dependent degradation
of syntaxin 1. These findings suggest that Staring is a
novel E3 ubiquitin-protein ligase that targets syntaxin 1
for degradation by the ubiquitin-proteasome pathway.
Modulation of protein degradation is a major mechanism by
which cells regulate the expression levels of specific proteins
and consequently the cellular processes that these proteins
participate in (1, 2). The ubiquitin-proteasome pathway plays a
crucial role in the degradation of proteins involved in a variety
of cellular processes, including differentiation, proliferation,
and apoptosis. However, the role of the ubiquitin-proteasome
pathway in the degradation of presynaptic proteins remains
poorly characterized, despite the presence of ubiquitin at nerve
terminals (3–5). In the ubiquitin-proteasome pathway, sub-
strates are marked for degradation by covalent linkage to ubiq-
uitin. The ubiquitinated substrate proteins are then recognized
and degraded by the 26 S proteasome (1, 2, 6). Ubiquitination
involves a highly specific enzyme cascade in which ubiquitin is
first activated by an E11 ubiquitin-activating enzyme and then
transferred to an E2 ubiquitin-conjugating enzyme and finally
ligated to the substrate by an E3 ubiquitin-protein ligase (1, 7,
8). The E3 ubiquitin-protein ligase plays an essential role in
determining the specificity of ubiquitination and subsequent
protein degradation. Consistent with this role, it is estimated
that an organism such as a human contains over 100 E3 ubiq-
uitin ligases, in contrast to a single E1 ubiquitin-activating
enzyme and about a dozen E2 ubiquitin-conjugating enzymes
(9). Despite the importance of E3 ubiquitin-protein ligases in
specific protein degradation and the estimated presence of
more than 100 E3 ligases in the human genome, only a few E3
ligases have been characterized at the molecular level.
Syntaxin 1 is a neuronal membrane protein that was origi-
nally identified as a binding partner for synaptotagmin and the
N-type calcium channel (10–12). It is well established that
syntaxin 1 functions as a synaptic t-SNARE to mediate synap-
tic vesicle exocytosis at nerve terminals (13–15). Syntaxin 1
appears early during embryonic development (16, 17), and its
expression level is dramatically up-regulated during synapse
formation and brain maturation (16–19). Regulation of syn-
taxin 1 levels may contribute to the mechanism underlying
learning and memory, since changes in syntaxin 1 levels have
been found to correlate with long term potentiation and various
learning and memory behaviors (20–22). Alteration in syntaxin
1 expression levels has been associated with several neurode-
generative diseases and psychiatric disorders, including schiz-
ophrenia, Alzheimer’s disease, and Creutzfeldt-Jakob disease
(23–26).
Despite the importance of the regulation of syntaxin 1 levels
in synaptic function and dysfunction, the molecular mecha-
nisms underlying such regulation remain undefined. To iden-
tify proteins that regulate syntaxin 1, we carried out a search
in rat brain for proteins that interact with syntaxin 1 using
yeast two-hybrid screens. Here we report the isolation of a
novel syntaxin 1-interacting protein, named Staring, that acts
as an E3 ubiquitin-protein ligase to promote the ubiquitination
and degradation of syntaxin 1 by the proteasome pathway.
EXPERIMENTAL PROCEDURES
Yeast Two-hybrid Screen and cDNA Cloning—The bait plasmid,
pPC97-Syntaxin 1, was constructed by subcloning the cytoplasmic do-
main (amino acids 5–270) of rat syntaxin 1B (27) into the pPC97 vector
(28, 29). For the two-hybrid screen, the yeast strain CG-1945
(CLONTECH) was transformed sequentially with pPC97-Syntaxin 1
and a rat hippocampal/cortical two-hybrid cDNA library (29), using the
lithium acetate method (30). Positive clones were selected on 3-amino-
triazole (5 mM; Sigma)-containing medium lacking leucine, tryptophan,
and histidine and verified with a filter assay for -galactosidase activ-
ity. Prey plasmids were then recovered and retransformed into yeast
with pPC97-Syntaxin 1 or various control baits to confirm the specific-
ity of the interaction. For cloning of full-length Staring, a partial Star-
ing cDNA probe from the prey clone (clone 7) was used to screen a rat
hippocampal cDNA library in ZAPII (Stratagene) according to the
standard procedure (31). The cDNA inserts from positive Staring clones
were sequenced multiple times on both strands using an Applied Bio-
systems 373A DNA sequencer.
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Expression Constructs—Conventional molecular biological tech-
niques (31) were used to subclone DNA fragments encoding full-length
and truncated forms of Staring into the following vectors: the pPC97
and pPC86 vectors for yeast two-hybrid interaction studies; the pro-
karyotic expression vectors pGEX-5X-2 (Amersham Biosciences) and
pET28c (Novagen) for the production of GST- and His6-tagged fusion
proteins; and the mammalian expression vectors pCDNA3.1() (In-
vitrogen) and pCHA (30) for transfection into HeLa cells. The expres-
sion construct pRK5-HA-UbcH5, pRK5-HA-UbcH7, and pRK5-HA-
UbcH8 were obtained as generous gifts from Dr. Ted Dawson (32).
Antibodies—Four polyclonal anti-Staring antibodies, two in chicken
(CS-N and CS-C) and two in rabbit (RS-N and RS-C), were generated
against Staring N-terminal peptide MSGLSNKRAAGDGG and C-ter-
minal peptide AAFGAHDFHRVYIS, respectively. The antibodies were
affinity-purified using the immunogen peptide-coupled columns as de-
scribed previously (30). Other antibodies used in this study include the
following: anti-HA (3F10 (Roche Molecular Biochemicals) and HA.11
(Covance)), anti-Myc (9E10.3; Neomarkers), anti-syntaxin 1 (HPC-1;
Sigma), anti-actin (C4; Roche Molecular Biochemicals) and secondary
antibodies coupled with horseradish peroxidase (Jackson Immunore-
search Laboratories, Inc.).
Northern and Western Blot Analyses—Northern blot analysis of Star-
ing mRNA expression was performed on a rat multiple tissue Northern
(MTNTM) blot and a human multiple tissue expression (MTETM) array
(CLONTECH), using a 32P-labeled Staring cDNA fragment from clone 7
as the probe (31). For Western blot analysis, rat tissues were homoge-
nized in 1% SDS and subjected to SDS-PAGE. The proteins were trans-
ferred onto nitrocellulose membranes and probed with anti-Staring and
other antibodies. Antibody binding was detected by using the enhanced
chemiluminescence system (Amersham Biosciences).
Subcellular Fractionations—Subcellular fractionations of rat brain
into cytosol fraction (100,000  g supernatant) and membrane fraction
(100,000  g pellet) were preformed as previously described (30). The
membrane fractions were subjected to extraction studies as described
(30), using 1.5 M NaCl or 4 M urea.
In Vitro Binding Assays—GST-Staring fusion proteins or GST con-
trol were immobilized on glutathione-agarose beads (Sigma) and incu-
bated with rat brain homogenates as previously described (30, 33).
After extensive washes, bound proteins were eluted by boiling in 2
Laemmli sample buffer and analyzed by SDS-PAGE and immunoblot-
ting with appropriate antibodies.
Cell Transfections and Immunoprecipitations—HeLa or SH-SY5Y
cells were transfected with indicated plasmids using LipofectAMINE
(Invitrogen) as described by the manufacturer. Cell lysates were pre-
pared and subjected to immunoprecipitation as described previously
(34), using anti-HA antibody (3F10), anti-Myc (9E10.3), anti-Staring
(RS-N), anti-syntaxin 1 antibody (HPC-1), or control IgG. The immu-
nocomplexes were recovered by incubation with protein G- or protein
A-Sepharose beads (Sigma). After extensive washes, the immunocom-
plexes were dissociated by boiling in the Laemmli sample buffer and
analyzed by SDS-PAGE and immunoblotting.
Ubiquitination Assays—HeLa cells were transfected with combina-
tions of the following plasmids: pCHA-syntaxin 1, pcDNA3-Myc-
ubiquitin, pFLAG-Staring, and pFLAG-StaringR, a C-terminal dele-
tion mutant of Staring that lacks the RING finger motif. SH-SY5Y cells
were transfected with pcDNA3-Myc-ubiquitin in combination with
pFLAG-Staring or pFLAG-StaringR. Twenty-four hours after trans-
fection, the cells were incubated for 8 h with 20 M MG132 (Calbio-
chem). The cells were then lysed, and an equal amount of protein from
each lysate was immunoprecipitated using antibodies against HA tag or
syntaxin 1 (34). Immunoprecipitates were analyzed by SDS-PAGE fol-
lowed by immunoblotting with an anti-Myc antibody to detect Myc-
ubiquitin conjugated to syntaxin 1.
[35S]Methionine Pulse-Chase Experiments—HeLa cells were co-
transfected with pCHA-syntaxin 1 and either pFLAG-Staring or
pFLAG vector control. SH-SY5Y cells were transfected with pFLAG-
Staring or pFLAG vector control. To control for the transfection effi-
ciency, cells were transfected using LipofectAMINE in a 150-mm cul-
ture dish. At 24 h post-transfection, the cells were divided into eight
60-mm dishes, each of which was used for a single chase time point. At
48 h post-transfection, cells in the 60-mm dishes were washed and
incubated for 30 min with Met/Cys-free DMEM. The medium was then
replaced with Met/Cys-free DMEM containing 200 Ci of [35S]Met/Cys
(1000 Ci/mmol) express protein labeling mix (PerkinElmer Life
Sciences). After incubation for 1 h, the radioactive medium was re-
moved by extensive washes with nonradioactive DMEM. Cells in each
60-mm dish were then incubated for the indicated chase time in non-
radioactive DMEM supplemented with 10% fetal bovine serum and 5
times the normal concentration of methionine and cysteine as described
previously (35). Cells were then lysed, and an equal amount of protein
from each lysate was immunoprecipitated using an anti-HA antibody.
Immunoprecipitates were resolved by SDS-PAGE and analyzed by a
PhosphorImager (Amersham Biosciences).
Proteolysis Inhibitor Treatment of Cells—HeLa or SH-SY5Y cells
expressing Staring and syntaxin 1 were incubated for 8 h at 37 °C with
the proteasome inhibitor MG132 (20 M; Calbiochem), the cysteine
protease inhibitor E-64 (50 M; Sigma), the lysosomal protease inhibitor
NH4Cl (50 mM) or chloroquine (100 M; Sigma), or vehicle (Me2SO; final
concentration 0.1%). Cells were then lysed, and the protein concentra-
tions of the lysates were determined by the BCA protein assay (Pierce).
An equal amount of protein from each lysate was then analyzed by
SDS-PAGE and immunoblotting.
RESULTS
Identification of Staring, a Novel Syntaxin 1-interacting
RING Finger Protein—To identify syntaxin 1-interacting pro-
teins, we screened a rat hippocampal/cortical cDNA library by
yeast two-hybrid selection using the cytoplasmic domain of rat
syntaxin 1B as bait. This screen led to the isolation of several
clones encoding SNAP-25, a known syntaxin 1-interacting pro-
FIG. 1. Structure of Staring. A, domain structure of Staring. Rat
Staring is a 1002-amino acid protein that contains six coiled-coil do-
mains (H1–H6) and a RING finger motif at the C terminus. The location
of the syntaxin 1-interacting clone (C7) isolated from the yeast two-
hybrid screen is indicated below the domain structure. For comparison,
the domain structure of human RBP95 is also shown. B, sequence of
Staring. The nucleotide sequence of Staring (not shown) was deposited
in the GenBankTM with accession number AF352815. The deduced
amino acid sequence of Staring is shown in single-letter code and
numbered on the left. Indicated are the predicted coiled-coil domains
(underline) and the RING finger motif (dotted line), in which key cys-
teine and histidine residues are marked with asterisks.
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tein (data not shown), confirming the validity of the two-hybrid
screen. One of the positive clones was shown to encode part of
a novel protein that we referred to as Staring (because it is a
syntaxin 1-interacting RING finger protein (Fig. 1A). Re-
transformation experiments confirmed that Staring interacts
specifically with syntaxin 1A and syntaxin 1B but not with
SNAP-25 or SNAP-23 (data not shown). Since SNAP-25 and
SNAP-23 contain coiled-coil t-SNARE domains that are ho-
mologous to the t-SNARE domain of syntaxin 1 (36), the
inability of Staring to interact with SNAP-25 and SNAP-23
further confirms the specificity of the Staring-syntaxin 1
interaction.
Cloning of the full-length Staring cDNA revealed that Star-
ing is a 1002-amino acid protein with a calculated molecular
mass of 113.8 kDa. The sequence surrounding the initiator
methionine codon of Staring conforms well to the translation
initiation consensus sequence (37) and is preceded by an in-
frame stop codon in the 5-untranslated region. Furthermore,
the coding sequence of Staring beginning with this methionine
initiator can be expressed in mammalian cells to yield a
recombinant protein with an apparent molecular weight sim-
ilar to that of endogenous Staring (data not shown), confirm-
ing that the cloned Staring sequence contains the entire
coding region. Staring is highly hydrophilic, with a theoreti-
cal isoelectric point (pI) of 6.13 and a high percentage (34%)
of charged amino acids over the entire length. Staring con-
tains neither a signal sequence nor a potential transmem-
brane domain.
As shown in Fig. 1, Staring contains six putative coiled-coil
domains and a RING finger motif at the C terminus. The RING
finger motif is a cysteine/histidine-rich (C3HC4), Zn
2 binding
domain that is found in a number of eukaryotic proteins, some
of which have been implicated in vesicular transport (38).
Emerging evidence indicates that the RING finger motif may
function in protein ubiquitination as a key determinant of the
E3 ubiquitin-protein ligase activity (39–41). The N-terminal
region of rat Staring is 90% identical to human RBP95, an
838-amino acid protein recently identified from a yeast two-
hybrid screen using retinoblastoma protein as bait (42). The
expression of endogenous RBP95 protein has not yet been
characterized; however, based on EST data base searches,
RBP95 seems to be a rare isoform derived from alternative
splicing of the gene encoding the uncharacterized human ring
finger protein 40 (RNF40, also called KIAA0661) (Fig. 2A).
Data base searches reveal the presence of Staring homo-
logues as uncharacterized cDNAs or open reading frames ob-
tained from genome projects in a number of organisms, includ-
ing humans, mice, Drosophila, Caenorhabditis elegans,
Arabidopsis, and yeast (Fig. 2A). Sequence comparison analy-
sis indicates that RNF40 is the human orthologue of rat Star-
ing. The human genome also contains a second Staring homo-
logue, RNF20, which is encoded by a gene that is distinct from
the RNF40 gene. In Drosophila, C. elegans, Arabidopsis, and
yeast, there appears to be only one Staring homologue.
Whereas the function of these Staring homologues is unknown,
the deletion mutant of the yeast Staring homologue, Bre1p
(also called YDL074c), was reported to be sensitive to multiple
drugs, including brefeldin A and chlorpromazine (43, 44). Anal-
ysis of the deduced proteins from the Staring-homologous se-
quences reveals that these homologous proteins have a domain
structure that is similar to that of Staring (Fig. 2A). Most
notably, these Staring homologues contain a highly conserved
RING finger motif at their C terminus (Fig. 2B). The conspic-
uous homology and conserved domain structure among Staring
homologues from different species indicate that Staring is an
evolutionarily conserved protein.
FIG. 2. Staring is an evolutionarily conserved protein. A, domain structure of the Staring homologues in different species. Predicted
coiled-coil domains are shown in striped boxes. The names and the lengths of the proteins are indicated along with their accession numbers. The
homology of these proteins to Staring is indicated by amino acid identity and similarity of each protein relative to the protein sequence of rat
Staring. B, alignment of the conserved RING finger motifs in the Staring homologues from different species. Numbers indicate the position of the
RING finger motif in each sequence. Conserved cysteine and histidine residues are marked with asterisks. Rn, Rattus norvegicus; Hs, Homo
sapiens; Mm, Mus musculus; Dm, Drosophila melanogaster; At, Arabidopsis thaliana; Ce, C. elegans; Sc, S. cerevisiae.
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Staring is a Ubiquitously Expressed Protein That Exists in
Both Cytosolic and Membrane-associated Pools—Northern blot
analysis of Staring mRNA expression revealed the presence of
a single Staring transcript of 5.1 kb (Fig. 3A). The Staring
mRNA is relatively abundant in brain, testis, heart, liver, and
kidney and expressed at low levels in lung, spleen, and skel-
etal muscle. Consistent with this result, analysis of human
Staring mRNA expression using a multiple tissue expression
array showed that Staring mRNA is ubiquitously expressed
in various brain regions as well as all fetal and adult human
tissues examined (data not shown). The broad tissue distri-
bution of Staring mRNA expression suggests that Staring
has a functional role important to many cell types, including
neurons.
To characterize Staring at the protein level, we generated
four polyclonal anti-Staring antibodies, two in chicken (CS-N
and CS-C) and two in rabbit (RS-N and RS-C), against the N-
and C-terminal 14-amino acid peptide of rat Staring, respec-
tively. The antibodies (CS-N and RS-N) against the N terminus
of Staring are expected to detect both Staring and RBP95
isoforms, whereas the antibodies (CS-C and RS-C) against the
C terminus of Staring should only recognize the Staring iso-
form. Western blot analysis demonstrated that all four anti-
Staring antibodies, but not their corresponding preimmune
controls, recognized a single endogenous protein band of 125
kDa (Fig. 3, B and C; data not shown), indicating that Staring
is the predominant isoform expressed in rat. No 95-kDa protein
band corresponding to RBP95 could be detected by either
chicken (CS-N) or rabbit (RS-N) antibodies against the N ter-
minus of Staring (Fig. 3B; data not shown), suggesting that
RBP95 is a rare isoform that is either expressed at extremely
low levels or not expressed at all. All four anti-Staring anti-
bodies specifically react with recombinant Staring protein
expressed in bacterial and mammalian cells (data not
shown). Furthermore, preabsorption of these anti-Staring
antibodies with recombinant Staring protein completely
eliminated their immunoreactivity to recombinant as well as
endogenous Staring protein (data not shown), confirming the
specificity of these antibodies. In agreement with the result
of Northern blot analysis (Fig. 3A), Western blot analysis
using the anti-Staring antibodies revealed that Staring pro-
tein is ubiquitously expressed in all tissues tested, although
the expression levels in heart and skeletal muscle are very
low (Fig. 3B).
To examine the intracellular distribution of endogenous
Staring, postnuclear supernatant of rat brain was separated
into cytosol and membrane fractions and then subjected to
Western blot analysis with anti-Staring antibodies (Fig. 3C).
Staring immunoreactivity was detected in both cytosol and
membrane fraction, although the relative amount of Staring in
FIG. 3. Distribution of Staring mRNA and protein expression in rat tissues. A, Northern blot analysis of Staring mRNA expression. A
multitissue Northern blot (CLONTECH) was hybridized with a 32P-labeled partial cDNA probe of Staring (upper panel). The loading of poly(A)
RNA in each lane was confirmed by hybridization of the same blot with a 32P-labeled -actin cDNA probe (lower panel). Sk., Skeletal. B, Western
blot analysis of Staring protein expression. Equal amounts of homogenates (50 g of protein/lane) from the indicated rat tissues were analyzed by
immunoblotting using antibodies against Staring (RS-N), syntaxin 1, syntaxin 4, or actin. C, Staring exists in both cytosolic and membrane-bound
pools. Postnuclear supernatant (T) from rat brain was separated in cytosol (C) and membrane (M) fractions. The membranes were extracted with
1.5 M NaCl or 4 M urea and then separated into soluble (S) and pellet (P) fractions. Aliquots representing an equal percentage of each fraction were
analyzed by SDS-PAGE and immunoblotting using anti-Staring antibody (RS-C).
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the cytosol fraction was severalfold more than that in the
membrane fraction. To investigate the nature of Staring as-
sociation with membranes, the membrane fraction was ex-
tracted with 1.5 M NaCl or 4 M urea (Fig. 3C). Unlike the
integral membrane protein syntaxin 1 that was resistant to
extraction by high salt and urea, a majority of Staring was
extracted by these treatments, suggesting that Staring is
peripherally associated with membranes via hydrophilic
interactions.
Staring Interacts with Syntaxin 1 in Vitro and in Vivo—To
determine whether the Staring-syntaxin 1 interaction detected
in yeast actually takes place in vitro, GST fusion proteins
containing various portions of Staring (Fig. 4A) were immobi-
lized on glutathione beads and used to bind endogenous syn-
taxin 1 from rat brain homogenate. As shown in Fig. 4B, the
GST-fusion proteins bearing the full-length Staring or the
Staring fragments that contain the predicted coiled-coil domain
H3 (Staring 1 and Staring 2) was able to bind endogenous
syntaxin 1. In contrast, the GST-Staring fusion protein con-
taining the coiled-coil domain H4 (Staring 3) or GST alone
was unable to pull down syntaxin 1, confirming that the ob-
served Staring-syntaxin 1 interaction is specific. These data
indicate that the syntaxin 1-binding site of Staring lies
within the H3 domain, between amino acid residues 448 and
536. In addition, other parts of Staring seem to also contrib-
ute to the interaction with syntaxin 1, since the GST-fusion
proteins containing truncated forms of Staring bound much
less syntaxin 1 than a similar amount of the full-length
GST-Staring (Fig. 4A).
To determine whether Staring associates with syntaxin 1 in
vivo, we first performed co-immunoprecipitation experiments
using lysates of HeLa cells expressing exogenous syntaxin 1
and HA-tagged Staring. As shown in Fig. 4C, syntaxin 1 and
HA-Staring were co-immunoprecipitated by the anti-HA anti-
body, providing evidence for the association of these two pro-
teins in mammalian cells. By comparison, control IgG was
unable to precipitate either syntaxin 1 or Staring. We then
performed additional co-immunoprecipitation experiments to
examine the association of endogenous Staring and syntaxin 1
in rat brain synaptosomes (Fig. 4D). Anti-syntaxin 1 antibody,
but not the mouse IgG control, was able to co-immunoprecipi-
tate syntaxin 1 and Staring from solubilized synaptosomes,
FIG. 4. Biochemical characterization of the interaction between Staring and syntaxin 1. A, schematic representation of Staring and its
deletion mutants encoded by GST fusion cDNA constructs used in the in vitro binding assays. B, Staring binds syntaxin 1 in vitro. GST-Staring
fusion proteins were immobilized on glutathione-Sepharose beads and incubated with rat brain homogenate (Input). After extensive washes, bound
proteins were eluted and analyzed by SDS-PAGE and immunoblotting for syntaxin 1 (upper panel). GST-Staring fusion proteins were shown as
Ponceau S staining (lower panel). C, co-immunoprecipitation of Staring with syntaxin 1 from transfected cells. Extracts from HeLa cells
co-transfected with pcDNA3-syntaxin 1 and pCHA-Staring were subjected to immunoprecipitation with an anti-HA antibody or control rat IgG.
Input, 30% of the HeLa extracts used for the immunoprecipitation. D, association of endogenous Staring with syntaxin 1 in rat brain. Detergent
extracts of rat brain synaptosomes (P2 fractions) were subjected to immunoprecipitation with anti-syntaxin 1 antibody or control mouse IgG.
Input, 30% of the brain extracts used for the immunoprecipitation. The immunoprecipitates in C and D were analyzed by immunoblotting with
anti-syntaxin 1 and anti-Staring (RS-C) antibodies. These co-immunoprecipitation experiments were replicated three times with similar results.
Novel E3 Ubiquitin Ligase Staring 35075
demonstrating the existence of endogenous Staring-syntaxin 1
complexes at nerve terminals. Under our experiment condi-
tions, 10% of total endogenous Staring was co-immunopre-
cipitated with syntaxin 1, indicating that only a fraction of
Staring and syntaxin 1 co-exist in the Staring-syntaxin 1 com-
plexes. These results are consistent with previous reports that
syntaxin 1 interacts with more than a dozen proteins, including
SNAP-25, nSec1/Munc-18, Munc-13, tomosyn, and syntaphilin
(14, 45–48). Moreover, as suggested by its multidomain struc-
ture, Staring is likely to interact with additional proteins.
Staring Binds and Recruits the E2 Ubiquitin-conjugating
Enzyme UbcH8 to Syntaxin 1—The presence of the RING fin-
ger motif in Staring raises the possibility that Staring may
function as an E3 ubiquitin-protein ligase via interaction with
a specific E2 ubiquitin-conjugating enzyme (41). As a first step
to test this possibility, Myc-tagged Staring was transiently
expressed in HeLa cells along with HA-tagged E2 enzyme
UbcH5, UbcH7, or UbcH8, and the interaction of these E2
enzymes with Staring was examined by co-immunoprecipita-
tion analysis (Fig. 5A). The results revealed that Staring spe-
cifically interacts with UbcH8, a brain-enriched E2 ubiquitin-
conjugating enzyme (49). In contrast, no appreciable inter-
action could be detected between Staring and UbcH5 or UbcH7.
These data indicate that UbcH8 is the cognate E2 ubiquitin-
conjugating enzyme for Staring. To further determine whether
Staring interacts with both UbcH8 and syntaxin 1 to form a
ternary complex, co-immunoprecipitation experiments were
performed using extracts of HeLa cells co-transfected with
epitope-tagged Staring, syntaxin 1, and UbcH8 (Fig. 5B). We
observed that syntaxin 1 and UbcH8 co-precipitate with Star-
ing in a stable complex, suggesting that Staring has the ability
to recruit its cognate E2 enzyme UbcH8 to syntaxin 1.
Staring Promotes the Ubiquitination of Syntaxin 1—Next,
we sought to determine whether Staring acts as an E3 ubiq-
uitin-protein ligase to ubiquitinate syntaxin 1 by using a well
established in vivo ubiquitination assay (50). HA-tagged syn-
taxin 1 was co-expressed in HeLa cells along with Myc-tagged
ubiquitin in the absence or presence of exogenous Staring. Cell
lysates were subjected to immunoprecipitation with an an-
ti-HA antibody followed by immunoblotting with an anti-Myc
antibody to detect ubiquitin-conjugated syntaxin 1 (Fig. 6).
Increased levels of Myc-tagged ubiquitin were detected on syn-
taxin 1 in the presence of exogenous Staring, indicating that
Staring promotes the ubiquitination of syntaxin 1. The Staring-
mediated ubiquitination seems to be polyubiquitination, be-
cause the ubiquitinated syntaxin 1 was detected as a high
molecular weight smear. In addition to the smear, several
predominant ubiquitination bands were observed, which may
represent predominant ubiquitinated syntaxin 1 species pro-
duced in vivo as the net result of the ubiquitination and deu-
biquitination reactions. Similar in vivo polyubiquitination pat-
terns have previously been seen with other ubiquitinated
proteins, such as synphilin-1 and CDCrel-1 (32, 51). The Myc-
FIG. 5. Staring binds selectively to UbcH8 and forms a ternary complex with syntaxin 1 and UbcH8. A, specific interaction between
Staring and UbcH8. HeLa cells were co-transfected with pcDNA3-Myc-Staring and pRK5-HA-UbcH5, pRK5-HA-UbcH7, or pRK5-HA-UbcH8. Cell
lysates of transfected cells were subjected to immunoprecipitation with an anti-Myc antibody. The immunoprecipitates were then analyzed by
immunoblotting with antibodies against HA, Myc, or actin. B, detection of a protein complex containing Staring, syntaxin 1, and UbcH8. Lysates
from HeLa cells co-transfected with pcDNA3-Myc-Staring, pcDNA3-syntaxin 1, and pRK5-HA-UbcH8 were immunoprecipitated with an anti-Myc
antibody followed by immunoblotting for Staring, syntaxin 1, HA-UbcH8, and actin.
FIG. 6. Staring is a RING-type E3 ubiquitin-protein ligase that
ubiquitinates syntaxin 1. HeLa cells were transfected with the indi-
cated plasmids and treated with MG132 (20 M) for 8 h before harvest.
Cell lysates were subjected to immunoprecipitation with an anti-HA
antibody followed by immunoblotting with an anti-Myc antibody to
detect Myc-ubiquitin conjugated to syntaxin 1. The blot was then
stripped and reprobed with an anti-syntaxin 1 antibody.
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immunoreactive band at 70 kDa is probably a nonspecific
band, because it also exists in the control lane that has no
Myc-tagged ubiquitin.
Since the RING finger motif is thought to be essential for the
enzymatic activity of a RING-type E3 ubiquitin-protein ligase
(40, 41), we examined the effect of deletion of the Staring RING
finger motif on the in vivo ubiquitination of syntaxin 1. A
mutant form of Staring (StaringR) that lacks the RING finger
motif was generated and analyzed for its ability to ubiquitinate
syntaxin 1 using the same in vivo ubiquitination assay as
described above (Fig. 6). The results revealed that deletion of
the RING finger motif abolished the ability of Staring to ubiq-
uitinate syntaxin 1, providing further evidence supporting the
role of Staring as a RING-type E3 ubiquitin-protein ligase.
Staring Targets Syntaxin 1 for Degradation by the Protea-
some Pathway—Polyubiquitination of a cellular protein gener-
ally leads to the degradation of the protein by the proteasome
pathway (52). To determine whether Staring-mediated ubiq-
uitination of syntaxin 1 promotes its degradation, we per-
formed pulse-chase experiments to compare the turnover rate
of syntaxin 1 protein in the absence and presence of exogenous
Staring. As shown in Fig. 7, the half-life of syntaxin 1 was
16.7 h in the absence of Staring. By comparison, the half-life
of syntaxin 1 was reduced to 6.1 h in the presence of Staring,
indicating that Staring has the ability to regulate the degra-
dation of syntaxin 1. Consistent with this result, measurement
of the syntaxin 1 protein level by Western blot analysis re-
vealed that the steady-state expression level of syntaxin 1 was
significantly decreased in the presence of Staring as compared
with the syntaxin 1 level in the absence of Staring (Fig. 7C).
Furthermore, the Staring-induced degradation of syntaxin 1
was blocked by MG132, a potent inhibitor of proteasome func-
tion (53), but not by E64, an inhibitor of lysosomal cysteine
proteases. Together, these results suggest that Staring pro-
motes the degradation of syntaxin 1 by the proteasome
pathway.
Staring Regulates the Ubiquitination and Degradation of
Endogenous Syntaxin 1 in SH-SY5Y Cells—We next investi-
gated whether Staring is able to regulate the ubiquitination
and degradation of endogenous syntaxin 1. For these studies,
we used human neuroblastoma SH-SY5Y cells, a well charac-
terized dopaminergic cell line that expresses endogenous syn-
taxin 1 and exhibits SNARE-mediated neurotransmitter re-
lease (54, 55). Overexpression of Staring in SH-SY5Y cells
significantly enhanced the ubiquitination of endogenous syn-
taxin 1, as indicated by the appearance of a high molecular
weight smear containing Myc-ubiquitin-modified syntaxin 1
(Fig. 8A). The effect of overexpressing Staring on syntaxin 1
ubiquitination was abolished by the deletion of Staring RING
finger motif, demonstrating that Staring promotes the ubiquiti-
nation of endogenous syntaxin 1 in a RING finger-dependent
manner. In addition, overexpression of Staring significantly
accelerated the turnover of endogenous syntaxin 1, as meas-
ured by the pulse-chase analyses in the absence and presence
of exogenous Staring (Fig. 8B). The half-life of endogenous
syntaxin 1 was reduced from 19.6 to 8.6 h by overexpression of
Staring. The increased turnover rate of syntaxin 1 was accom-
panied by a decrease in the steady-state expression level of
syntaxin 1 in the presence of exogenous Staring (Fig. 8C).
Moreover, the Staring-induced degradation of endogenous syn-
taxin 1 was blocked by the proteasome inhibitor MG132 but not
by the lysosomal protease inhibitor E-64, NH4Cl, or chloro-
quine (Fig. 8C). Taken together, these data provide strong
support for a role of Staring in regulating the degradation of
endogenous syntaxin 1 via the ubiquitin-proteasome pathway.
DISCUSSION
Whereas it is becoming increasingly clear that the ubiquitin-
proteasome proteolytic pathway is involved in synaptic func-
tion and neurodegeneration (56–58), very little is known about
neuronal protein substrates that are targeted by this pathway.
On the other hand, alterations in the expression levels of pre-
synaptic proteins have been linked to synaptic plasticity and
neurodegeneration, yet it is not understood whether and how
the ubiquitin-proteasome proteolytic pathway regulates the
degradation of these proteins at nerve terminals. In this study,
we have identified and characterized Staring, a novel RING
finger protein that interacts with syntaxin 1, an essential com-
ponent of neurotransmitter release machinery. Our data sug-
gest that Staring may function as an E3 ubiquitin-protein
FIG. 7. Staring accelerates proteasome-mediated degradation
of exogenous syntaxin 1 expressed in HeLa cells. A, degradation of
syntaxin 1 in the presence or absence of exogenous Staring. HeLa cells
were co-transfected with pCHA-syntaxin 1 and either pFLAG vector or
pFLAG-Staring. Forty-eight hours after transfection, the cells were
pulse-labeled for 1 h with DMEM containing [35S]Met/Cys, chased with
nonradioactive Met/Cys for the indicated time, and then lysed. 35S-
Labeled syntaxin 1 was immunoprecipitated with a monoclonal an-
ti-HA antibody and detected by SDS-PAGE and autoradiography. B,
levels of syntaxin 1 were measured by quantification of the intensity of
the 35-kDa syntaxin 1 band using a PhosphorImager and plotted rela-
tive to the amount of syntaxin 1 present at 0 h. Data are shown as
mean  S.E. (error bar) of the results from three independent experi-
ments. C, effect of Staring on syntaxin 1 degradation was blocked by
proteasome inhibitors. HeLa cells were co-transfected with
pcDNA3-syntaxin 1 and pCHA-Staring or pCHA vector control. Twen-
ty-four hours later, cells were incubated for 8 h at 37 °C with Me2SO
(DMSO), proteasome inhibitor MG132 (20 M in Me2SO), or cysteine
protease inhibitor E64 (50 M). Cells were then lysed, and an equal
amount of protein from each lysate was analyzed by immunoblotting for
syntaxin 1 and actin.
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ligase to promote the ubiquitination and degradation of syn-
taxin 1 by the proteasome pathway.
Traditionally, it is thought that the lysosomal pathway is
used for the degradation of transmembrane proteins like syn-
taxin 1, whereas the ubiquitin-proteasome pathway is involved
in the degradation of cytosolic and nuclear proteins. However,
several recent papers reported the involvement of the ubiq-
uitin-proteasome pathway in the degradation of transmem-
brane proteins, such as GABAA receptor, Netrin-1 receptor
DCC (deleted in colorectal cancer), amiloride-sensitive epithe-
lial Na channels, and the Epstein-Barr virus latent mem-
brane protein 1 (LMP1) (59–63). In addition, our recent work
has demonstrated that the degradation of synaptic vesicle
membrane protein synaptophysin is regulated by the E3 ubiq-
uitin-protein ligase Siah in a proteasome-dependent manner
(35). The evidence presented here suggests that the ubiquitin-
proteasome pathway also regulates the degradation of the
plasma membrane t-SNARE syntaxin 1. These findings impli-
cate an important role for the ubiquitin-proteasome pathway in
the degradation of both cytosolic and membrane proteins at
nerve terminals. Since in neuron the lysosome is localized in
the cell body instead of the nerve terminal, degradation by the
ubiquitin-proteasome pathway may provide a more efficient
means for the regulation of presynaptic protein levels locally at
the nerve terminal.
Staring is a novel member of a growing family of RING finger
proteins that function as E3 ubiquitin-protein ligases. The
RING type E3 ligases consist of two classes: single-subunit
RING E3 ligases and multisubunit RING E3 ligases. A single
subunit RING E3 ligase contains the substrate-binding domain
and the RING finger motif in the same molecule. In contrast, a
multisubunit RING E3 ligase is a multiprotein complex that
contains the RING finger protein as one subunit and a separate
protein for substrate recognition (41, 64). Our data indicate
that Staring is a single-subunit RING E3 ligase that uses its
coiled-coil domain H3 to bind substrate syntaxin 1. In addition
to the H3 domain, Staring also contains five other coiled-coil
domains, suggesting that Staring may bind and ubiquitinate
additional substrates.
Among the molecular components of the ubiquitin-protea-
some pathway, the E3 ubiquitin-protein ligase is perhaps the
most important player, because it binds specific substrates and
determines their ubiquitination and subsequent degradation.
Furthermore, regulation of the E3-mediated substrate recogni-
tion and ubiquitination is a major mechanism for modulation of
specific protein degradation (52, 64). Aberrations in the E3
ubiquitin-protein ligase activities have been implicated in the
pathogenesis of several human diseases (64). For example,
mutations or exon deletions in the gene encoding the E3 ubiq-
uitin-protein ligase parkin are a major cause of autosomal
recessive juvenile parkinsonism (58, 65, 66). Interestingly, par-
kin is widely expressed in many tissues, yet autosomal reces-
sive juvenile parkinsonism is characterized by a selective de-
generation of nigral neurons, suggesting that accumulation of a
neuron-specific substrate(s) may be involved in the pathogen-
esis (65, 66). Similar to parkin, Staring is also ubiquitously
expressed. We have found that Staring selectively interacts
with the brain-enriched E2 ubiquitin-conjugating enzyme
UbcH8 and promotes the ubiquitination and degradation of the
neuron-specific protein syntaxin 1. Since altered syntaxin 1
levels have been associated with several neurodegenerative
diseases, it would be tempting to speculate that Staring-medi-
ated syntaxin 1 degradation contributes to the pathophysiology
of these diseases. Further studies of the molecular mechanism
that controls the degradation of presynaptic proteins will not
only enhance our understanding of neurodegeneration but will
also advance our knowledge of synaptic plasticity such as
learning and memory.
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FIG. 8. Overexpression of Staring promotes the ubiquitination and degradation of endogenous syntaxin 1 in SH-SY5Y cells. A,
Staring ubiquitinates endogenous syntaxin 1 in vivo. Lysates of SH-SY5Y cells transfected with indicated plasmids were subjected to immuno-
precipitation with an anti-syntaxin 1 antibody followed by immunoblotting with an anti-Myc (upper panel) or anti-syntaxin 1 (lower panel)
antibodies. B, Staring accelerates the turnover of endogenous syntaxin 1. SH-SY5Y cells transfected with pFLAG-Staring or pFLAG vector were
pulse-labeled for 1 h with [35S]Met/Cys and chased with nonradioactive medium for indicated times. 35S-Labeled syntaxin 1 was immunoprecipi-
tated with anti-HA antibody, detected by autoradiography (upper panel), and quantified with a PhosphorImager (lower panel). Data are shown as
mean  S.E. (error bar) of the results from three independent experiments. C, Staring-induced degradation of syntaxin 1 is sensitive to proteasome
inhibition. SH-SY5Y cells transfected with pCHA-Staring or pCHA vector control were treated for 8 h before harvest with 0.1% Me2SO, 20 M
MG132, 50 M E64, 50 mM NH4Cl, or 100 M chloroquine. An equal amount of protein from each lysate was analyzed by immunoblotting for
syntaxin 1 and actin.
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